title: [High-dose chemotherapy in the treatment of children with malignant lymphoma].
abstract: BACKGROUND
  Children with primary refractory or recurrent malignant lymphoma have usually poor prognosis. Less than 10% of those, who were treated with conventional-dose regimens had survived for 2 years. In an attempt to improve the outcome for these patients, we explored the role of consolidation high-dose chemotherapy with autografting.
  
  
  RESULTS
  Forty-five patients with poor-prognosis lymphoma, of whom 27 were males, underwent megatherapy between January 1992 and December 1999. High-dose chemotherapy was indicated in patients with poor initial response to first-line chemotherapy (14 cases) or in the relapse (31 cases). The group consisted of 27 patients with Hodgkin's disease and 18 patients with non-Hodgkin's lymphoma. The median age was 14.7 years. The conditioning for Hodgkin's disease patients contained cyclophosphamide, etoposide and busulfan or carmustine. Patients with non-Hodgkin's lymphomas received cyclophosphamide, etoposide and busulfan or total body irradiation. Bone marrow was used as the source of haemopoietic stem cells in ten patients, peripheral blood in twenty-eight, and both sources were used in seven patients. After the median follow-up of 47 months, the final survival was 61%. Eleven patients died of the disease progression, four of the infectious complications, one at a car accident. Median time to relapse after the transplantation was 7.5 months.
  
  
  CONCLUSIONS
  Further improvement of these results will require earlier transplantation, improved preparative regiments or early posttransplant immunotherapy.
authors.affiliation: Klinika dĕtské onkologie 2. LF UK a FNM, Praha.
authors.forename: E
authors.initials: E
authors.lastname: Kabícková
authors.forename: P
authors.initials: P
authors.lastname: Kavan
authors.forename: J
authors.initials: J
authors.lastname: Koutecký
authors.forename: J
authors.initials: J
authors.lastname: Malis
authors.forename: J
authors.initials: J
authors.lastname: Stanková
authors.forename: P
authors.initials: P
authors.lastname: Gajdos
authors.forename: R
authors.initials: R
authors.lastname: Kodet
authors.forename: E
authors.initials: E
authors.lastname: Cumlivská
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D015996:Survival Rate
vernacular_title: Vysokodávkovaná chemoterapie v lécbĕ dĕtí s maligním lymfomem.